International Journal of Healthcare Sciences ISSN 2348-5728 (Online)
Vol. 4, Issue 2, pp: (692-698), Month: October 2016 - March 2017, Available at: www.researchpublish.com

Acute Ischemic Stroke, Etiology and Complications; Overview

[1]Elaf Mohammed Albasheri, [2]Jawaher Ibrahim Alqurashi,
[3]Sahar Abdulrahman alyamani, [4]Samaa Majed, [5]Fawziah Ali halawani,
[6]Abdulrahman alamodi

Abstract: **Stroke is the number one cause of adult life impairment in the United States and Europe and is the third leading cause of death in the United States. Around 15% of strokes are hemorrhagic and 85% are ischemic. This study aimed to overview and demonstrate the etiology and risk factors of Acute Ischemic Stroke, and we also aimed to review the most common complication associated with AIS, or following it. A comprehensive search was conducted through major databases; Ovid MEDLINE, Ovid EMBASE, Ovid Cochrane Central Register of Controlled Trials, through December, 2016,). The search strategy used Mesh terms; stroke, ischemic stroke, transient ischemic stroke, combined with Etiology, AND Complications. Conference proceedings of major neurology, neurosurgery, and stroke organizations were searched manually to identify relevant abstracts and potential articles. Markers of inflammation have been revealed to be risk markers of stroke. In epidemiological studies, the leukocyte count was connected with the risk of first-time myocardial infarction and ischemic stroke, a result that was independent of smoking cigarettes and other vascular risk factors shown in several studies. stroke risk factors may influence the interaction between inflammatory cells and the surrounding resident cerebrovascular cells, causing increased susceptibility to inflammatory stimulation and to the development of atheromatous plaques in big arteries and intimal thickening with local apoplexy in smaller arterioles.**

Keywords: **Ovid MEDLINE, Ovid EMBASE, Ovid Cochrane, Acute ischemic stroke, Etiology and complications.**

1. INTRODUCTION

Stroke is the number one cause of adult life impairment in the United States and Europe and is the third leading cause of death in the United States. Around 15% of strokes are hemorrhagic and 85% are ischemic [(1)]. Severe ischemic stroke (AIS) is a heterogeneous group of vascular diseases that includes large-artery atherosclerosis (16.3%), penetrating small-artery disease (lacunar infarcts, 15.9%), cardiogenic embolism (29.1%), stroke of unknown etiology (36.1%), and stroke of other identified etiology (2.6%) [(2)]. A stroke may occur in the arterial or venous vasculature and may be due to either intracranial or extracranial disease and it takes place when a cerebral vessel occludes, blocking blood circulation to a part of the brain [(2)]. Large-artery strokes might arise from atherogenic embolus or hypoperfusion. These strokes may manifest with big embolisms concerns and more serious baseline neurologic deficit and, as a consequence, might fail traditional AIS interventions [(1)]. Malignant middle cerebral artery (MCA) occlusions represent a special subtype of large-artery strokes, the symptom which differs from that of other AIS cases [(3)].

In addition to the preliminary neuronal damage, neurological and medical issues following intense ischemic stroke could be independent predictors for unfavorable functional outcome and death after 3 months [(4)]. One problem of optimized care in stroke systems for that reason is the prevention and treatment of early complications in order to minimize negative outcome results and prolongation of medical facility stay. Apart from the specific medical experience, understanding on beginning and course of common problems following intense ischemic stroke is for that reason mandatory to determine the period of close tracking and severe care. Several analyses on adverse occasions in randomized trials have actually been released, however can be generalized only with caution since these patients were picked inning accordance with particular study criteria and had to consent to take part in a scientific trial [(5,6)]. On the other hand, hospital-based accomplice studies in patients with severe ischemic stroke in the past have actually just been too little or retrospective to provide representative information on less frequent issues [(7,8)].

This study aimed to overview and demonstrate the etiology and risk factors of Acute Ischemic Stroke, and we also aimed to review the most common complication associated with AIS, or following it.

2. METHODS

A comprehensive search was conducted through major databases; Ovid MEDLINE, Ovid EMBASE, Ovid Cochrane Central Register of Controlled Trials, through December, 2016,). The search strategy used Mesh terms; stroke, ischemic stroke, transient ischemic stroke, combined with Etiology, AND Complications. Conference proceedings of major neurology, neurosurgery, and stroke organizations were searched manually to identify relevant abstracts and potential articles. we also searched references of potentially eligible articles were reviewed to identify all potentially eligible articles. and we limited our search in English language, and human trails only.

3. RESULTS & DISCUSSION

Risk factors of Acute Ischemic Stroke:

The conventional stroke risk factors, including hypertension, diabetes mellitus, cigarette smoking, and cardiac diseases, do not fully account for the danger of stroke, and stroke victims, particularly young topics, frequently do not have any of these factors. Geographic heterogeneity, seasonal prevalence in stroke incidence throughout fall or winter months found in the majority of studies, and the decrease of stroke during the 20th century is just incompletely described by standard threat factors and their temporal patterns [8,9,10,11,12]. Inflammatory specifications and acute and persistent contagious diseases have actually been thought about to customize stroke risk independent of traditional risk aspects. Although the roots of this subject return as far as the 19th century, the conversation has actually highly heightened throughout the last 5 to 10 years, with numerous new insights being gathered nearly every month. Nevertheless, outcomes are often conflicting, and it appears progressively hard to keep abreast of this quickly advancing field. Stroke is an etiologically heterogeneous disease, but atherosclerosis contributes to a large percentage of cases either straight via aortic, cervical, or intracranial large-artery atherosclerosis or indirectly by cardio-embolism, e.g., as a result of heart arrhythmias caused by coronary heart problem (CHD) or emboli after myocardial infarction. Atherosclerosis is today viewed as a persistent inflammatory vascular condition, [13] and infectious diseases are thought to add to its pathophysiology.

Arterial hypertension is possibly the sturdiest stroke risk factor; appropriately, antihypertensives are most potent in stroke avoidance. The association of chronically or acutely raised blood pressure with markers of swelling is well documented. Circulating levels of sICAM-1, soluble vascular cell adhesion molecule-1 (sVCAM-1), and sE-selectin have been reported to be increased in patients with vital high blood pressure [14,15]. Acute high blood pressure induced by cold pressor test in normotensive and hypertensive patients increased serum levels of se-selectin, sicam-1, and svcam-1 but did not influence the expression of adhesion molecules in flowing monocytes and lymphocytes [16]. Chronic hypertension including structural organ renovation is also associated with signs of activation in monocytes gotten from peripheral blood [17]. Surprisingly, another research study recommended that circulating monocytes from patients with high blood pressure are preactivated compared to those in nonhypertensive controls [18]. On stimulation with lipopolysaccharide (LPS) or angiotensin II, these preactivated monocytes released more TNF-α than those from normotensives (**Figure1**) [33]. Risk factors may worry vascular function through additive, and even synergistic impacts, which involve systemic inflammation. Certainly, cross-sectional observations are consistent with the hypothesis that unusual vascular function in type 2 diabetes in hypertensive topics is at least in part secondary to increased inflammation, with associated EC and platelet activation [19].

Smoking is generally held to be immunosuppressive, however, in association with a prohemostatic risk factor, smoking might be a pro-inflammatory factor (**Figure1**) [33]. Monocyte expression of TF was found to be increased in smoking cigarettes women as well as more so in those utilizing contraceptive pills, which was based upon induction of NF-κB in monocytes [20]. Cigarette smoking increased distributing levels of sICAM-1 and decreased the variety of activated flowing monocytes, which may suggest augmented cell-cell adhesion [21]. In a population currently harboring ischemic cerebrovascular disease, those who smoked had actually increased levels of sICAM-1 and sE-selectin [22]. Cross-sectional research studies also revealed associations in between vascular risk factors, including diabetes cigarette smoking, mellitus, and hyperlipidemia, and inflammatory indexes such as leukocyte count, C-reactive protein (CRP), and fibrinogen [22,23].

Etiology of AIS:

Infectious Endocarditis and other infections as serious etiology of Acute Ischemic Stroke;

Infectious endocarditis is an endovascular, microbial infection of the intracardiac structures (native or prosthetic) and of the large intrathoracic vessels [24] resulting from a complicated interaction among the microbial representative and the matrix particles and platelets on the damaged endocardial surface area. Rough circulation, produced by hereditary or obtained cardiac disease, harms the endothelium, predisposing to platelet and fibrin deposition. The resultant plant life of an initially nonbacterial thrombotic endocarditis is colonized by the microbial representative present in the blood stream, resulting in infectious endocarditis [25]. The most common etiology of transmittable endocarditis is bacterial; fungal etiology is uncommon (,6% of all cases) [26,27]. Candida albicans represents the main etiology of fungal endocarditis, non-Albicans species have actually been reported in intravenous drug abusers and diabetics [26,27]. Neurologic issues associated with infectious endocarditis happen with an incidence that has stayed largely the same over the last century; 20%-40% of patients with infectious endocarditis develop stroke, meningitis, sleeping sickness, seizures, and encephalopathy, alone or in combination [28]. Stroke is by far the most regular issue of contagious endocarditis (42%), with occurrence before the initiation of antimicrobial treatment in 76% of cases and as the most common presentation indication of contagious endocarditis in 47% of cases [28,29].

Monogenic diseases can cause AIS:

Monogenic diseases are responsible of about 5% of stroke cases [29]. However, the portion is most likely to be underestimated because of the diagnostic complexity and the high phenotypic irregularity of these conditions. There are more than 50 monogenic diseases that can trigger stroke [29] [**Table 1**] [30,31,32]. Acknowledgment of people and households bring mutations triggering Mitochondrial or Mendelian diseases with stroke as a phenotypic symptom remains an important difficulty for clinicians. Mendelian disorders can be acknowledged by their familial aggregation, reasonably young age of beginning, more extreme medical course, and greater reoccurrence rates, compared with sporadic diseases [30,31].

Table1: Common mutations in monogenic diseases for details see the text. adapted from [30,31,32]

Monogenic diseases	Involved genes	Genes functions
MELAS	tRNA (Leu) A3243G	Mitochondrial tRNA
tRNA (Leu) T3271C	Mitochondrial tRNA	[23]
	tRNA (Lys) A8344G	Mitochondrial tRNA
Familial hemiplegic migraine	CACNA1A	Encoding the alpha1A sub-unit of the voltage-gated calcium channels in neurons
CADASIL	NOTCH3	Unknown
CARASIL	HTRA1	Protease
FABRY	α-GAL A	Encoding α-galactosidase A enzyme
Small vessel disease	COL4A1	Encoding the α1[IV]-chain of type IV collagen
HERNS	TREX1	Encoding three-prime repair exonuclease 1
Stroke and vasculopathy with ADA2 mutations	CECR1	Encoding the ADA2 protein (important for endothelial and leukocyte development and differentiation)
Homocystinuria	Multiple genes encoding different enzymes	Deficiencies of this enzymes can cause very high plasma concentrations of homocysteine and homocystinuria
Sickle cell disease	Haemoglobin beta chain gene	Encoding for beta chain of normal haemoglobin (mutation of this gene causes polymerization or aggregation of abnormal hemoglobin -. HbS - within red blood cells)
Vascular Ehlers-Danlos syndrome	COL3A1	Encoding collagen type III
Marfan syndrome	FBN1	Encoding fibrillin 1
Pseudoxanthoma elasticum	ABCC6	ATP-binding cassette C6



Figure1: Traditional risk factors, genetic predisposition, and chronic and acute infection/inflammation appear to be linked tightly to each other and influence the likelihood of thrombotic events. Coincidental occurrences of multiple factors may increase the likelihood of precipitation of stroke [33].

Complications associated with AIS:

Medical complications happen in 30% to 60% of patients after an intense ischemic stroke [34]. Urinary and pulmonary system infections and deep vein thrombosis are among the more typical. Acquiring a swallowing examination prior to oral medications and nutrition, preventing positioning and early removal of indwelling bladder catheters, and usage of mechanical and pharmacologic prophylaxes for deep vein apoplexy can decrease the likelihood of these complications [35]. Roughly 20% of strokes are persistent occasions. Efficient secondary avoidance depends upon management of basic stroke risk factors (e.g., high blood pressure, hyperlipidemia, obesity, cigarette smoking cessation) and recognition of specific conditions that might have triggered the stroke (e.g., atrial fibrillation, carotid stenosis). The management of these and other prospective reasons for stroke are evaluated in current secondary avoidance standards [36].

The procedure of healing begins as quickly as the patient is stabilized. Although strategies differ, multidisciplinary rehab is associated with enhanced functional result after stroke (five additional patients returned home in an independent state for each 100 treated), consisting of reductions in death (OR = 0.66, 95% CI, 0.49-0.88), death or institutionalization (OR = 0.70, 95% CI, 0.56-0.88), and death or dependence (OR = 0.65, 95% CI, 0.50-0.85) [37].

The frequency of post-stroke anxiety differs amongst research studies, depending upon diagnostic criteria and the qualities of the research study friend.48 One potential research study discovered that 10% to 20% of patients were depressed 3 months after stroke.48 Recognition of depression is necessary as it adds to post-stroke morbidity and is frequently undertreated [38]. A minimum of one study found that treatment with fluoxetine caused enhanced practical outcome after stroke [39].

Anxiety is the most common psychiatric condition impacting patients with stroke and may contribute to post-stroke morbidity and mortality [40]. The frequency of post-stroke depression varies considerably across research studies depending upon mate characteristics and diagnostic requirements but is substantially higher than control populations matched for age and sex [41,42,43,44]. The pathophysiology of post-stroke depression is likely multifactorial and affected by

the area and extent of brain injury, vascular comorbidities, and response to new functional disability [45,46]. Patients with short-term ischemic attack (TIA) share comorbid conditions with those who have had an ischemic stroke, and although roughly 30% to 40% might have radiographically shown brain injury, by meaning, a TIA is not connected with a long-lasting functional problems. However, there is a paucity of studies examining the proportional frequency of anxiety and antidepressant usage amongst patients with TIA [47,48].

4. CONCLUSION

Markers of inflammation have been revealed to be risk markers of stroke. In epidemiological studies, the leukocyte count was connected with the risk of first-time myocardial infarction and ischemic stroke, a result that was independent of smoking cigarettes and other vascular risk factors shown in several studies. stroke risk factors may influence the interaction between inflammatory cells and the surrounding resident cerebrovascular cells, causing increased susceptibility to inflammatory stimulation and to the development of atheromatous plaques in big arteries and intimal thickening with local apoplexy in smaller arterioles.

REFERENCES

[1] Adams HP Jr, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke: definitions for use in a multicenter clinical trial—TOAST, trial of Org 10172 in acute stroke treatment. Stroke 1993;24:35–41.

[2] Petty GW, Brown RD Jr, Whisnant JP, Sicks JD, O'Fallon WM, Wiebers DO. Ischemic stroke subtypes: a population-based study of incidence and risk factors. Stroke 1999;30:2513–16.

[3] Adams HP Jr, del Zoppo G, Alberts MJ, et al. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association stroke council, clinical cardiology council, cardiovascular radiology and intervention council, and the atherosclerotic peripheral vascular disease and quality of care outcomes in research interdisciplinary working groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke 2007;38:1655–711.

[4] Weimar C, Ziegler A, König IR, Diener HC: Predicting functional outcome and survival after acute ischemic stroke. J Neurol 2002;249: 888–895.

[5] van der Worp HB, Kappelle LJ: Complications of acute ischaemic stroke. Cerebrovasc Dis 1998;8:124–132.

[6] Johnston KC, Li JY, Lyden PD, Hanson SK, Feasby TE, Adams RJ, Faught RE Jr, Haley EC Jr: Medical and neurological complications of ischemic stroke: Experience from the RANTTAS trial. RANTTAS Investigators. Stroke 1998;29:447–453.

[7] Langhorne P, Stott DJ, Robertson L, MacDonald J, Jones L, McAlpine C, Dick F, Taylor GS, Murray G: Medical complications after stroke: A multicenter study. Stroke 2000;31:1223– 1229.

[8] Howard G, Howard VJ, Katholi C, Oli MK, Huston S. Decline in US stroke mortality: an analysis of temporal patterns by sex, race, and geographic region. Stroke. 2001; 32: 2213–2220.

[9] Kelly-Hayes M, Wolf PA, Kase CS, Brand FN, McGuirk JM, d'Agostino RB. Temporal patterns of stroke onset: the Framingham Study. Stroke. 1995; 26: 1343–1347.

[10] Jakovljevic D, Salomaa V, Sivenius J, Tamminen M, Sarti C, Salmi K, Kaarsalo E, Narva V, Immonen-Räihä P, Torppa J, Tuomilehto J. Seasonal variation in the occurrence of stroke in a Finnish adult population: the FINMONICA Stroke Register. Stroke. 1996; 27: 1774–1779.

[11] Bonita R, Beaglehole R. Does treatment of hypertension explain the decline in mortality from stroke? BMJ. 1986; 292: 191–192.

[12] lag MJ, Whelton PK, Seidler AJ. Decline in US stroke mortality: demographic trends and antihypertensive treatment. Stroke. 1989; 20: 14–21.

[13] Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999; 340: 115–126.

[14] Blann AD, Tse W, Maxwell SJ, Waite MA. Increased levels of the soluble adhesion molecule E-selectin in essential hypertension. J Hypertens. 1994; 12: 925–928.

[15] DeSouza CA, Dengel DR, Macko RF, Cox K, Seals DR. Elevated levels of circulating cell adhesion molecules in uncomplicated essential hypertension. Am J Hypertens. 1997; 10: 1335–1341.Medline

[16] Buemi M, Allegra A, Aloisi C, Corica F, Alonci A, Ruello A, Montalto G, Frisina N. Cold pressor test raises serum concentrations of ICAM-1, VCAM-1, and E-selectin in normotensive and hypertensive patients. Hypertension. 1997; 30: 845–847.

[17] Porreca E, Di Febbo C, Mincione G, Reale M, Baccante G, Guglielmi MD, Cuccurullo F, Colletta G. Increased transforming growth factor-beta production and gene expression by peripheral blood monocytes of hypertensive patients. Hypertension. 1997; 30: 134–139.

[18] Dorffel Y, Latsch C, Stuhlmüller B, Schreiber S, Scholze S, Burmeister GR, Scholze J. Preactivated peripheral blood monocytes in patients with essential hypertension. Hypertension. 1999; 34: 113–117.

[19] Woodman RJ, Watts GF, Puddey IB, Burke V, Mori TA, Hodgson JM, Beilin LJ. Leukocyte count and vascular function in type 2 diabetic subjects with treated hypertension. Atherosclerosis. 2002; 163: 175–181.

[20] Holschermann H, Terhalle HM, Zakel U, MausU, Parviz B, Tillmans H, Haberbosch W. Monocyte tissue factor expression is enhanced in women who smoke and use oral contraceptives. Thromb Haemost. 1999; 82: 1614–1620.

[21] Bergmann S, Siekmeier R, Mix CD, Jaross W. Even moderate cigarette smoking influences the pattern of circulating monocytes and the concentration of sICAM-1. Respir Physiol. 1998; 114: 269–275.

[22] Grau AJ, Buggle F, Becher H, Werle E, Hacke W. The association of leukocyte count, fibrinogen and C-reactive protein with vascular risk factors and ischemic vascular diseases. Thromb Haemost. 1996; 82: 245–255.

[23] Mendall MA, Patel P, Ballam L, Strachan D, Northfield TC. C reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study. BMJ. 1996; 312: 1061–1065.

[24] Horstkotte D, Follath F, Gutschik E, et al. Task Force on Infective Endocarditis of the European Society of Cardiology. Guidelines on prevention, diagnosis and treatment of infective endocarditis: Executive summary. Eur Heart J 2004;25:267-276.

[25] Wilson W, Taubert KA, Gewitz M, et al. Prevention of infective endocarditis: Guidelines from the American Heart Association. Circulation 2007;116:1736-1754.

[26] Garzoni C, Nobre VA, Garbino J. Candida parapsilosis endocarditis: A comparative review of the literature. Eur J Clin Microbiol Infect Dis 2007;26:915-926.

[27] Li CS, Huang CR, Lu CH, et al. Concomitant stroke and Candida parapsilosis native valve endocarditis: Report of one case and literature review. Acta Neurol Taiwan 2004;13:131-135.

[28] Anderson DJ, Goldstein LB, Wilkinson WE, et al. Stroke location, characterization, severity, and outcome in mitral versus aortic valve endocarditis. Neurology 2003; 61:1341-1346.

[29] J.M. Ferro, A.R. Massaro, J.-L. Mas. Aetiological diagnosis of ischaemic stroke in young adults. Lancet Neurol., 9 (2010), pp. 1085–1096

[30] Y. Goto, S. Horai, T. Matsuoka, Y. Koga, K. Nihei, M. Kobayashi, I. Nonaka. Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS): A correlative study of the clinical features and mitochondrial DNA mutation. Neurology, 42 (1992), pp. 545–550

[31] P. Kaufmann, K. Engelstad, Y. Wei, R. Kulikova, M. Oskoui, V. Battista, D.Y. Koenigsberger, J.M. Pascual, M. Sano, M. Hirano, S. DiMauro, D.C. Shungu, X. Mao, D.C. De Vivo. Protean phenotypic features of the A3243G mitochondrial DNA mutation. Arch. Neurol., 66 (1) (2009), pp. 85–91.

[32] A. Federico, I. Di Donato, S. Bianchi, *et al.*Hereditary cerebral small vessel diseases: A review. J. Neurol. Sci., 322 (1–2) (2012), pp. 25–30

[33] Perttu J. Lindsberg and Armin J. Grau. Inflammation and Infections as Risk Factors for Ischemic Stroke. Stroke. 2003; 34:2518 2532.

[34] Kumar S, Selim MH, Caplan LR. Medical complications after stroke. Lancet Neurol. 2010 Jan;9(1):105–18.

[35] Jauch EC, Saver JL, Adams HP Jr, Bruno A, Connors JJ, Demaerschalk BM, et al. Guidelines for the early management of patients with acute ischemic stroke: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013 Jan 31;44:870–947.

[36] Furie KL, Kasner SE, Adams RJ, Albers GW, Bush RL, Fagan SC, et al. ; American Heart Association Stroke Council, Council on Cardiovascular Nursing, Council on Clinical Cardiology, and Interdisciplinary Council on Quality of Care and Outcomes Research. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011 Jan;42(1):227–76.

[37] Langhorne P, Duncan P. Does the organization of postacute stroke care really matter? Stroke. 2001 Jan;32(1):268–74.

[38] El Husseini N, Goldstein LB, Peterson ED, Zhao X, Pan W, Olson DM, et al. Depression and antidepressant use after stroke and transient ischemic attack. Stroke. 2012 Jan;43(6):1609–16.

[39] Chollet F, Tardy J, Albucher JF, Thalamas C, Berard E, Lamy C, et al. Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial. Lancet Neurol. 2011 Feb;10(2):123–30.

[40] hemerinski E, Levine SR. Neuropsychiatric disorders following vascular brain injury. *Mt Sinai J Med*. 2006; 73: 1006–1014.

[41] Hackett ML, Yapa C, Parag V, Anderson CS. Frequency of depression after stroke: a systematic review of observational studies. *Stroke*. 2005; 36: 1330–1340.

[42] House A, Dennis M, Mogridge L, Warlow C, Hawton K, Jones L. Mood disorders in the year after first stroke. *Br J Psychiatry*. 1991; 158: 83–92.

[43] Wade DT, Legh-Smith J, Hewer RA. Depressed mood after stroke. A community study of its frequency. *Br J Psychiatry*. 1987; 151: 200–205.

[44] Dieguez S, Staub F, Bruggimann L, Bogousslavsky J. Is poststroke depression a vascular depression? *J Neurol Sci*. 2004; 226: 53–58.

[45] Hackett ML, Anderson CS. Predictors of depression after stroke: a systematic review of observational studies. *Stroke*. 2005; 36: 2296–2301.

[46] Poynter B, Shuman M, Diaz-Granados N, Kapral M, Grace SL, Stewart DE. Sex differences in the prevalence of post-stroke depression: a systematic review. *Psychosomatics*. 2009; 50: 563–569.

[47] Wu KY, Liu CY, Chau YL, Chang CM. Transient ischemic attack and incidence of depression in old age: evidence from a population-based analysis in Taiwan. *Am J Geriatr Psychiatry*. 2010; 18: 382–387.

[48] Luijendijk HJ, Stricker BH, Wieberdink RG, Koudstaal PJ, Hofman A, Breteler MM, et al. Transient ischemic attack and incident depression. *Stroke*. 2011; 42: 1857–1861.